STOCK TITAN

Lisata Therapeutics Inc - LSTA STOCK NEWS

Welcome to our dedicated news page for Lisata Therapeutics (Ticker: LSTA), a resource for investors and traders seeking the latest updates and insights on Lisata Therapeutics.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Lisata Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Lisata Therapeutics's position in the market.

Rhea-AI Summary
Lisata Therapeutics, Inc. (Nasdaq: LSTA) has completed enrollment in the Phase 2b ASCEND study of its novel agent, LSTA1, for the treatment of metastatic pancreatic ductal adenocarcinoma. Top-line data is expected in the fourth quarter of 2024, with complete data by mid-2025. The trial evaluates the efficacy of LSTA1 in combination with standard-of-care gemcitabine and nab-paclitaxel in patients with metastatic pancreatic ductal adenocarcinoma.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
12.6%
Tags
-
Rhea-AI Summary
Lisata Therapeutics, Inc. (Nasdaq: LSTA) announced that David J. Mazzo, PhD, President and CEO, will present at NobleCon19, Noble Capital Markets’ Nineteenth Annual Emerging Growth Equity Conference, on December 4, 2023. The company is developing innovative therapies for advanced solid tumors and serious diseases.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.01%
Tags
conferences
-
Rhea-AI Summary
Lisata Therapeutics, Inc. (Nasdaq: LSTA) announced that its President and CEO, Dr. David J. Mazzo, will present at LSX Inv€$tival Showcase 2023 in London, UK on November 13, 2023, discussing innovative therapies for advanced solid tumors and serious diseases.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.84%
Tags
conferences
Rhea-AI Summary
Lisata Therapeutics announced significant clinical progress in studies evaluating LSTA1, including first patients treated in BOLSTER trial and continued rapid enrollment in ASCEND. Orphan drug designations granted for LSTA1 in malignant glioma (U.S.) and pancreatic cancer (EU). Lisata expects to have topline data from Cohort A of ASCEND as early as Q4 2024, a year earlier than anticipated. Expected cash runway projects into early 2026.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.26%
Tags
-
Rhea-AI Summary
Lisata Therapeutics, Inc. will report its Q3 2023 financial results on November 2, 2023, after the market closes. A conference call will be held at 4:30 p.m. Eastern time.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.48%
Tags
conferences earnings
-
Rhea-AI Summary
Lisata Therapeutics has announced the treatment of the first patient in the cholangiocarcinoma cohort of the BOLSTER Trial, a Phase 2a study evaluating LSTA1 in combination with standard-of-care versus standard-of-care alone in subjects with advanced solid tumors. The trial is expected to be completed in the second half of 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.87%
Tags
none
Rhea-AI Summary
Lisata Therapeutics receives orphan drug designation for pancreatic cancer treatment
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.6%
Tags
-
Rhea-AI Summary
Lisata Therapeutics' CEO to present at upcoming conferences in October.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.96%
Tags
conferences
-
Rhea-AI Summary
Gregory Berkin, CIO of Lisata, to discuss CISO leadership and AI risks at InfoSec World 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.98%
Tags
none
Rhea-AI Summary
Lisata Therapeutics announces treatment of first patient in head and neck squamous cell carcinoma cohort of BOLSTER trial
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.51%
Tags
none
Lisata Therapeutics Inc

Nasdaq:LSTA

LSTA Rankings

LSTA Stock Data

24.09M
6.75M
19%
8.93%
0.2%
Biological Product (except Diagnostic) Manufacturing
Manufacturing
Link
US
Basking Ridge

About LSTA

caladrius biosciences, inc., a clinical-stage biopharmaceutical company, develops cellular therapeutic product candidates to address diseases and conditions caused by ischemia. its product candidates include developmental treatments for cardiovascular diseases, such as clbs12 for the treatment of critical limb ischemia; clbs16, which is in phase ii clinical trial for the treatment of coronary microvascular dysfunction; clbs14, a regenerative medicine advanced therapy for treating no-option refractory disabling angina. the company was formerly known as neostem, inc. and changed its name to caladrius biosciences, inc. in june 2015. caladrius biosciences, inc. was founded in 1980 and is headquartered in basking ridge, new jersey.